Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Marrow transplantation as salvage therapy in non-Hodgkin's lymphoma seems to be superior to chemotherapy administered in conventional doses, although trials are ongoing. Transplantation results are better when refractory and relapsed patients respond to conventional salvage therapy (sensitive relapse) and residual disease is reduced to a minimum. The authors summarize clinical findings to date, including the latest work with interferon and monoclonal antibodies.

Original languageEnglish (US)
Pages (from-to)11-21
Number of pages11
JournalOncology (Williston Park, N.Y.)
Volume1
Issue number9
StatePublished - Nov 1 1987

Fingerprint

Salvage Therapy
Non-Hodgkin's Lymphoma
Transplantation
Interferons
Bone Marrow
Monoclonal Antibodies
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

@article{552f4c3b8abc43188bfc25b184f4fd49,
title = "Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.",
abstract = "Marrow transplantation as salvage therapy in non-Hodgkin's lymphoma seems to be superior to chemotherapy administered in conventional doses, although trials are ongoing. Transplantation results are better when refractory and relapsed patients respond to conventional salvage therapy (sensitive relapse) and residual disease is reduced to a minimum. The authors summarize clinical findings to date, including the latest work with interferon and monoclonal antibodies.",
author = "Bierman, {Philip Jay} and Armitage, {James Olen}",
year = "1987",
month = "11",
day = "1",
language = "English (US)",
volume = "1",
pages = "11--21",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9",

}

TY - JOUR

T1 - Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

AU - Bierman, Philip Jay

AU - Armitage, James Olen

PY - 1987/11/1

Y1 - 1987/11/1

N2 - Marrow transplantation as salvage therapy in non-Hodgkin's lymphoma seems to be superior to chemotherapy administered in conventional doses, although trials are ongoing. Transplantation results are better when refractory and relapsed patients respond to conventional salvage therapy (sensitive relapse) and residual disease is reduced to a minimum. The authors summarize clinical findings to date, including the latest work with interferon and monoclonal antibodies.

AB - Marrow transplantation as salvage therapy in non-Hodgkin's lymphoma seems to be superior to chemotherapy administered in conventional doses, although trials are ongoing. Transplantation results are better when refractory and relapsed patients respond to conventional salvage therapy (sensitive relapse) and residual disease is reduced to a minimum. The authors summarize clinical findings to date, including the latest work with interferon and monoclonal antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0023440552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023440552&partnerID=8YFLogxK

M3 - Review article

VL - 1

SP - 11

EP - 21

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9

ER -